Last reviewed · How we verify
CASAD
At a glance
| Generic name | CASAD |
|---|---|
| Also known as | Calcium Aluminosilicate Anti-Diarrheal. |
| Sponsor | Salient Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan (PHASE2)
- CASAD for Severe Diarrhea in the Emergency Department (NA)
- Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection (PHASE2)
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CASAD CI brief — competitive landscape report
- CASAD updates RSS · CI watch RSS
- Salient Pharmaceuticals Incorporated portfolio CI